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 Abstract
Background: Macrolides are considered safe antibiotics with reduced allergenic activity. However, studies on the safety of macrolides are 
scarce, particularly in children.
Objective: The aim of this study was to assess the frequency of hypersensitivity reactions to clarithromycin and azithromycin in a group of 
children referred to our allergy unit for suspected macrolide allergy.
Methods: We retrospectively reviewed the charts of 90 children aged 1-17 years with symptoms suggestive of hypersensitivity reaction 
to clarithromycin or azithromycin between December 31, 2008 and December 31, 2013. The allergy workup included skin tests (ie, skin 
prick tests and/or intradermal tests), determination of serum specific IgE (sIgE) to clarithromycin and azithromycin, and, if necessary to 
reach a diagnosis, oral provocation tests.
Results: Seventy-seven children completed the allergy workup. A reaction to clarithromycin was recorded in 58 children (75.3%): 21 (36.2%) 
had a history of immediate reactions, and 37 (63.8%) had a history of nonimmediate reactions. A reaction to azithromycin was recorded 
in 19 children (24.6%): 6 (31.5%) had a history of immediate reaction, and 13 (68.42%) had a history of nonimmediate reaction. Positive 
results in skin tests and oral provocation tests with the suspect drug confirmed the diagnosis in 15.5% of reactions to clarithromycin (9 
of 58) and in 47.3% of reactions to azithromycin (9 of 19) (P=.004).
Conclusion: A complete allergy workup enabled us to confirm a diagnosis of clarithromycin and azithromycin allergy in 15.5% and 47.3% 
of cases, respectively. Azithromycin was more allergenic than clarithromycin in children.
Key words: Azithromycin. Children. Clarithromycin. Drug hypersensitivity. Macrolides.
 Resumen
Antecedentes: A los macrólidos se les considera antibióticos seguros, con una reducida capacidad alergénica. Sin embargo, los estudios 
sobre este tema son insuficientes, especialmente en los niños.
Objetivo: El objetivo de este estudio ha sido el evaluar la frecuencia de reacciones hipersensibilidad (HR) a claritromicina (clarithromycin) 
y a azitromicina (azithromycin) en un grupo de niños, estudiados en nuestra Unidad de Alergia, por sospecha de alergia a los macrólidos.
Métodos: Se han estudiado restrospectivamente, 90 niños (de 1-17 años) con síntomas sugestivos de HR a clarithromycin o azithromycin, 
entre el 31 de diciembre de 2008 y 31 de diciembre de 2013. En el protocolo de estudio se incluyeron la realización de pruebas cutáneas 
intraepidérmicas (prick, SPT) y/o pruebas intradérmicas (ID)], la determinación de IgE sérica específica (sIgE) a clarithromycin y azithromycin 
y, si se consideraba necesario para llegar a un diagnóstico, pruebas de provocación oral (OPT).
Resultados: Setenta y siete niños completaron el estudio. Cincuenta y ocho (75,3%) referían haber presentado reacciones a clarithromycin: 
21 (36,2%) tenían antecedentes de reacciones inmediatas (IR), y 37 (63,8%) tenían antecedentes de reacciones no inmediatas (RIN). 
Diecinueve de los 77 niños (24,6%) habían presentado una reacción a azithromycin: 6 (31,5%) con una historia de IR y 13 (68,42%) con 
historia de NIR. Mediante pruebas cutáneas o por positividad en la OPT con el fármaco sospechoso, permitió confirmar el diagnóstico en 
15,5% (9 de 58) de los casos de clarithromycin y en 47,3% (9 de 19) de los casos de azithromycin (p= 0,004).
Conclusión: Un estudio alergológico completo permitió realizar un correcto diagnóstico de alergia a clarithromycin y azithromycin en 
15,5% y 47,3% de los casos, respectivamente. En este trabajo, en niños, la azithromycin fue más alergénica que la clarithromycin.
Palabras clave: Azitromicina. Niños. Claritromicina. Hipersensibilidad a fármacos. Macrolides.
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Introduction
Macrolides are a group of related compounds that have a 
lactone ring (14 to 16 atoms) bonded to one or more deoxy 
sugar molecules [1]. They have bacteriostatic and bactericidal 
activity, good cell penetrance, and anti-inflammatory and 
immunomodulatory effects [2]. In addition, they are active 
against most of the bacteria that cause community-acquired 
pneumonia, such as gram-positive bacteria, which include 
penicillinase-producing staphylococci, and atypical pathogens 
(ie, Mycoplasma and Chlamydia species). Macrolides are 
generally well tolerated, and allergy to macrolides is an 
uncommon event (occurring in 0.4%-3% of treatments). In 
children, macrolides are widely used to treat community-
acquired infections of the lower and upper airways [3-4]. 
Immediate reactions occur within the first hour after 
intake [5]. Nonimmediate reactions occur at any time between 
1 hour and 72 hours after intake [6].
In a recent study [7], we showed that allergy to 
clarithromycin is not uncommon (detected in 4 of 64 [6%] 
children with a history of adverse reactions to clarithromycin). 
The frequency of adverse reactions to azithromycin has 
increased recently, most likely owing to the rapid increase in 
use over the last 10 years [8].
The aim of the present study was to assess the frequency of 
hypersensitivity reactions to clarithromycin and azithromycin 
in a group of children referred to our allergy unit for possible 
allergic reaction to macrolides.
Methods
We retrospectively reviewed charts from 90 patients (mean 
age, 8.5 years; range, 1-17 years) who were referred to the 
Allergy Unit of A. Meyer Children’s Hospital, Florence, Italy 
for suspected hypersensitivity reaction to clarithromycin or 
azithromycin between December 31, 2008 and December 31, 
2013. The allergy workup was performed according to current 
recommendations for antibiotic allergy [6,9].
Skin tests with clarithromycin and azithromycin were performed 
at the first visit. The concentrations used for skin prick tests (SPT) 
and intradermal tests (IDT) were 50 mg/mL and 0.5-0.05 mg/mL, 
respectively, in normal saline for clarithromycin and 100 mg/mL 
and 0.1 and 0.01 mg/mL, respectively, in normal saline for 
azithromycin [10].
We prepared a powder-based intravenous solution of 
clarithromycin and azithromycin no more than 2 hours before 
testing. SPT was initially performed with 1 drop of each of the 
aforementioned reagents on the volar surface of the forearm 
at increasing concentrations. The reactions were considered 
positive when a wheal larger than 3 mm in diameter with 
surrounding erythema appeared after 10 minutes.
When the SPT result was negative, IDT was performed by 
injecting 0.03 mL of the reagent solution into the volar surface 
of the forearm. Readings were obtained at 20 minutes and at 24, 
48, and 72 hours after the injection. The results were considered 
positive if the initial wheal diameter increased by >3 mm with 
a flare. Positive controls for SPT and IDT were performed 
with histamine (at 10 and 1 mg/mL, respectively). Normal 
saline was used as a control for negative SPT and IDT results. 
Drug-specific IgE was determined using radioimmunoassay. 
According to the method of Baldo and Harle [11], the solid 
phase was obtained by coupling the drug (clarithromycin 
or azithromycin) to epoxy-activated sepharose 6B through 
a spacer arm. The results are expressed as the ratio of 
radioactivity in the detecting antibody bound to the solid phase 
to the total amount of radioactivity introduced. Values of at 
least 3 times the level of normal serum (taken from healthy, 
nonatopic individuals) were considered positive. Patients 
with positive SPT or IDT results were considered allergic, 
independently of the radioimmunoassay result. 
The oral provocation test (OPT) was performed as an open 
challenge with the suspect drug in all patients with negative 
in vivo test results. At the time of the OPT, all patients were 
in their usual state of health, with no signs of acute or chronic 
infection and clear skin. Patients had to be off antihistamines 
for at least 7 days and off corticosteroid or immunosuppressive 
therapy for the previous 30 days. At the first visit, the OPT was 
performed by calculating the therapeutic dose (clarithromycin 
7.5 mg/kg and azithromycin 10 mg/kg) divided into 3 doses 
(1/10, 2/10, and 7/10 administered every 30 minutes). After 
the last dose, the patients were kept under observation for at 
least 2 hours to monitor for adverse events. On the following 
day, the therapeutic dose was administered at once, and the 
patients were observed for 3 hours. In the case of cutaneous or 
respiratory symptoms or alterations in vital signs (heart rate, 
blood pressure, breathing rate), the challenge was stopped, and 
appropriate treatment was initiated. In patients with a history 
of nonimmediate reactions, the challenge was continued for 
5 days at a therapeutic dose every 12 hours for clarithromycin 
and every 24 hours for azithromycin. Patients were provided 
with antihistamines and oral corticosteroids and a telephone 
number that they could use to contact us in case of adverse 
reactions. Written informed consent was obtained from all 
parents. Institutional review board approval was not required.
All statistical analyses were performed using SPSS version 
22 (IBM Corp). Qualitative variables were compared using 
the chi-square test. Statistical significance was set at P<.01.
Results
The allergy workup was incomplete in 13 cases: 10 patients 
refused to undergo OPT, 3 had moved to another town.
Among the 77 children who completed the allergy 
workup, 58 (75.3%) had a history of hypersensitivity reaction 
to clarithromycin and 19 (24.6%) to azithromycin. Among 
the patients with a history of reaction to clarithromycin, 
21 (36.2%) had an immediate reaction and 37 (63.8%) a 
nonimmediate reaction; in the patients with suspected reaction 
to azithromycin, 6 (31.5%) had an immediate reaction and 
13 (68.42%) a nonimmediate reaction (Figure).
Skin manifestations were the most commonly reported 
symptoms (76.2%) in the 21 children with an immediate 
reaction to clarithromycin: 6 patients (37.5%) experienced 
urticaria, 5 (31.5%) urticaria-angioedema, 2 (12.5%) 
maculopapular rash, 1 (6.25%) eczema, and 2 (12.5%) 
undefined rash. Four patients (19.4%) presented gastrointestinal 
symptoms, and 1 patient (5%) presented respiratory symptoms 
(bronchospasm). The SPT with clarithromycin was positive in 
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Thirteen patients with a history of nonimmediate reaction to 
azithromycin reported the following symptoms: maculopapular 
rash, 7 (53.8%); urticaria, 1 (7.6%); erythema, 1 (7.6%); 
itching, 1 (7.6%); abdominal pain, 1 (7.6%); and asthma, 
1 (7.6%). Five of the 13 patients with a nonimmediate reaction 
to azithromycin (38%) had a positive IDT result at the late 
reading and were therefore considered to have nonimmediate 
hypersensitivity to azithromycin. The remaining 8 patients 
underwent an OPT, which yielded negative results (Figure).
Therefore, 9 of the 19 (47%) patients who experienced 
a hypersensitivity reaction to azithromycin were considered 
allergic (4/6 with an immediate reaction and 5/13 with a 
nonimmediate reaction).
In total, 9 of 58 patients (15.5%) had a positive skin test 
or OPT result to clarithromycin, and 9 of 19 patients (47.3%) 
had a positive skin test or OPT result to azithromycin (P=.004) 
(Table).
1 child. The 20 patients with a negative SPT result underwent 
IDT: readings at 20 minutes were positive in 1 patient. Of the 21 
children with positive skin testing results, 2 (1 with a positive 
SPT result and 1 with a positive IDT result) were considered 
to be allergic. Both of these children also had positive serum 
specific IgE for clarithromycin. The 19 patients with negative 
skin test results and negative serum sIgE to clarithromycin 
underwent the OPT with clarithromycin, and the results were 
negative (Figure).
Among the 37 children with nonimmediate reactions to 
clarithromycin, 32 (87%) experienced cutaneous symptoms, 
including 17 patients (53%) with maculopapular rash, 7 (22%) 
with undefined rash, 5 (16%) with urticaria, 2 (6%) with 
urticaria-angioedema, 1 (3%) with exfoliative dermatitis, 
2 (5%) with gastrointestinal symptoms, and 3 (8%) with 
respiratory symptoms (bronchospasm). Five of the 37 patients 
(13.5%) with nonimmediate reactions to clarithromycin had 
a positive IDT result and were diagnosed as allergic. The 32 
children with a negative skin test result underwent OPT, which 
was positive in 2 patients (6.25%) (Figure).
Therefore, 9 of the 58 patients (15.5 %) with a history 
of hypersensitivity reaction were considered allergic to 
clarithromycin (7 patients were identified through skin testing, 
and 2 patients were identified through OPT).
Among the 6 patients with an immediate reaction to 
azithromycin, 3 had a history of mild anaphylactic reaction: 
of these, 2 presented urticaria-angioedema (33.3%) associated 
with vomiting or wheezing, and 1 had angioedema (16.6%) 
with wheezing and dyspnea, as described by Mori et al [12].
Four of these 6 patients had positive skin test results (1 had 
a positive SPT result, and 3 had positive IDT results). Four 
patients had sIgE to azithromycin (3 patients with a positive skin 
test result and 1 with a negative skin test result). The only patient 
with a negative skin test result and positive sIgE to azithromycin 
underwent OPT, which produced negative results. When the 
correlation between skin testing and sIgE levels was assessed 
in the 6 patients with an immediate reaction to azithromycin, 
we found that the positive predictive value (PPV) was 75% and 
the negative predictive value (NPV) was 50%.
Table. Skin Test or Oral Provocation Test Results in Patients With a History 
of Allergic Reaction to Clarithromycin and Azithromycin 
 Positive ST or  Total No. % 
 OPT, No. of Patients  
CL  9 58 15.5
AZT 9 19 47.3
Total 18 77 26.8
Abbreviations: AZT, azithromycin; CL, clarithromycin; OPT, oral 
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Figure. Results of the allergology workup. CL indicates clarithromycin; AZT, azithromycin; IR, immediate reaction; NIR, nonimmediate reaction; ST, skin 
test (skin prick test or intradermal test); OPT, oral provocation test;        test stopped.
Discussion
Allergy to macrolides is considered an uncommon event, 
and urticaria is the most frequent clinical manifestation [5]. 
Severe reactions to these compounds—including anaphylaxis 
in the case of erythromycin [13], clarithromycin [14], and 
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telithromycin [15]—are rare. A case of drug reaction with 
eosinophilia and systemic symptoms was reported in an 
8-year-old boy with acute Epstein-Barr virus infection who 
took azithromycin [16]. Cases of contact dermatitis [17,18] 
and hypersensitivity syndrome [19] have also been described.
The consumption of macrolides, particularly those with 
long half-lives (azithromycin), has increased in Italy over 
the last few years [8]. Clarithromycin has been reported to be 
associated with a lower number of adverse reactions than other 
macrolides such as erythromycin [20], but no comparison with 
azithromycin has been reported.
In a previous study [7], we demonstrated clarithromycin 
allergy in 4 out of 64 children (6%) with previously reported 
adverse reactions due to clarithromycin. 
The possibility of anaphylaxis to clarithromycin is 
very low. Specifically, the incidence of anaphylaxis to 
clarithromycin reported in the literature is 1 case per 1 million 
per year in pediatric studies [21].
In the present study, we found that 9/58 (15.5%) children 
with suspected clarithromycin allergy had their diagnosis 
confirmed by positive results in skin tests, sIgE, or OPT.
Two of the 22 children with a history of immediate reaction 
presented positive skin test results and were considered to have 
IgE-mediated hypersensitivity reaction. However, the real PPV 
of a positive skin test result is unknown, because OPT was not 
performed as recommended in these cases (6,9). The 19 patients 
with a history of immediate reactions and negative skin test 
results all had negative OPT results. Of the 32 patients with 
nonimmediate reactions and negative skin test results, 30 had a 
negative OPT result, and 2 had a positive OPT result. Therefore, 
the NPV of skin testing for immediate and nonimmediate 
reactions clarithromycin was 100% and 94%, respectively. 
Azithromycin is considered a well-tolerated drug in all 
age groups. In one study [22], the incidence of adverse events 
was 12%, with most such events affecting the gastrointestinal 
tract. Skin eruptions have also been reported [23], as have 
IgE-mediated anaphylactic reactions to azithromycin [12], 
contact reactions [17,18], and hypersensitivity reactions [19]. 
We showed that hypersensitivity reaction to azithromycin 
can occur and that an allergy workup should be performed. 
Four of the 6 patients (66.6%) with immediate reactions had 
positive results for an immediate skin test reading, and 5 of the 
13 patients (38%) with a nonimmediate reaction had positive 
results for a late skin test reading.
All 8 patients with negative skin test results had negative 
results in OPT, thus confirming the elevated NPV of a negative 
skin test result for both clarithromycin and azithromycin.
Ours is the first study to demonstrate that azithromycin is 
more allergenic than clarithromycin in children and that this 
difference is statistically significant (Table). We show that 
9 of the 58 patients studied (15.5%) had positive skin test or 
OPT results to clarithromycin and that 9 of the 19 (47.3%) had 
positive skin test results to azithromycin. 
Allergy workups for suspected macrolide hypersensitivity 
are not standardized, particularly those used for azithromycin. 
When diagnosing azithromycin allergy, we used the nonirritant 
concentrations suggested by the only study published to date 
in this area [10]. However, the fact that the 3 patients with 
anaphylactic reactions to azithromycin all had positive skin 
test results confirmed the adequacy of the concentrations used, 
at least in immediate reactions.
Additional studies have investigated the nonirritant IDT 
concentration for diagnosing clarithromycin allergy. Sanchez-
Morillas et al [24] considered the intradermal concentration of 
0.1 mg/mL of clarithromycin as nonirritant, although they did 
not provide data on the control group. Broz et al [25] used laser 
Doppler flowmetry and found 0.05 mg/mL to be the nonirritant 
intradermal skin test concentration for clarithromycin. 
In the only study [7] in which the skin results correlated 
with the OPT results, the threshold nonirritant intradermal 
concentration of clarithromycin was 0.5 mg/mL, with a 
sensitivity of 75% and specificity of 90%. In the present study, 
using the same threshold concentration, we found that 7 of 
58 children (12%) with reported reactions to clarithromycin 
had positive results to skin tests or OPT. However, because 
the OPT was not performed in these cases, the possibility of 
false-positive results should be considered.
Few studies have assessed sIgE to macrolides in suspected 
allergy [13,26]. In the present study, however, determination 
of sIgE using epoxy-activated sepharose 6B appears to be 
promising, particularly in cases of immediate reaction to 
azithromycin, where high concordance was observed with 
positive skin test results. When the results of skin testing to 
sIgE levels were correlated among patients with immediate 
reactions to azithromycin, we found a PPV of 75%, thus 
demonstrating the utility of this determination in the allergy 
workup for patients with immediate reactions.
In conclusion, allergy workups for cases of suspected 
macrolide hypersensitivity should be encouraged and based 
on a detailed medical history to avoid inappropriate exclusion 
of this important class of drugs. Moreover, the combination 
of skin tests, in vitro tests, and OPT to the suspect drug may 
lead to a greater understanding of the mechanisms underlying 
macrolide allergy and increase the sensitivity of the entire 
diagnostic workup.
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